Tiragolumab and atezolizumab: Objective response rate in NSCLC

Tiragolumab and atezolizumab showed improved objective response rate over tiragolumab and placebo in chemotherapy-naïve locally advanced or metastatic non-small cell lung cancer (NSCLC).

Tiragolumab and atezolizumab showed improved objective response rate over tiragolumab and placebo in chemotherapy-naïve locally advanced or metastatic non-small cell lung cancer (NSCLC).

Dr. Delvys Rodriguez-Abreu (NYU Perlmutter Cancer Center, USA) presented the phase 2 CITYSCAPE trial, which tested patients with chemotherapy-naïve PD-L1-positive locally advanced or metastatic NSCLC [1]. Participants were randomized to the combination of tiragolumab and atezolizumab (n=67) versus placebo plus atezolizumab (n=68). Co-primary endpoints were investigator-assessed objective response rate (ORR) and progression-free survival (PFS).

The primary analysis indicated that tiragolumab/atezolizumab improved ORR and median PFS compared with tiragolumab/placebo. The ORR was 31.3% in the tiragolumab arm versus 16.2% in the placebo arm. The median PFS was 5.4 months and 3.6 months in the tiragolumab and placebo arms, respectively (HR 0.57). 

According to the updated analysis, the ORR was 37.3% versus 20.6% in the tiragolumab and placebo arms, respectively. Investigators also stratified patients according to the PD-L1 tumor proportion score (TPS between 1% and 49% versus at least 50%). Patients with a PD-L1 TPS of at least 50% derived even more benefit from tiragolumab/atezolizumab with an ORR of 66% versus 24% with atezolizumab alone.

Source:
1. Rodriguez-Abreu, D et al. Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE) ASCO Virtual Meeting, 29-31 May 2020, Abstract 9503.

Esanum is an online network for approved doctors

Esanum is the medical platform on the Internet. Here, doctors have the opportunity to get in touch with a multitude of colleagues and to share interdisciplinary experiences. Discussions include both cases and observations from practice, as well as news and developments from everyday medical practice.

Esanum ist ein Online-Netzwerk für approbierte Ärzte

Esanum ist die Ärzteplattform im Internet. Hier haben Ärzte die Möglichkeit, mit einer Vielzahl von Kollegen in Kontakt zu treten und interdisziplinär Erfahrungen auszutauschen. Diskussionen umfassen sowohl Fälle und Beobachtungen aus der Praxis, als auch Neuigkeiten und Entwicklungen aus dem medizinischen Alltag.

Esanum est un réseau en ligne pour les médecins agréés

Esanum est un réseau social pour les médecins. Rejoignez la communauté et partagez votre expérience avec vos confrères. Actualités santé, comptes-rendus d'études scientifiques et congrès médicaux : retrouvez toute l'actualité de votre spécialité médicale sur esanum.